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Two decades of studies in multiple model organisms have established the Hippo pathway as a key
regulator of organ size and tissue homeostasis. By inhibiting YAP and TAZ transcription co-activa-
tors, the Hippo pathway regulates cell proliferation, apoptosis, and stemness in response to a wide
range of extracellular and intracellular signals, including cell-cell contact, cell polarity, mechanical
cues, ligands of G-protein-coupled receptors, and cellular energy status. Dysregulation of the
Hippo pathway exerts a significant impact on cancer development. Further investigation of the
functions and regulatory mechanisms of this pathway will help uncovering the mystery of organ
size control and identify new targets for cancer treatment.The emergence of multicellular organisms is an evolutionary
milestone. Among the most fundamental mechanisms support-
ing multicellularity are those that ensure the proper size and
shape of tissues and organs to meet the need of functionality.
However, despite intensive investigations into the underlying
principles behind a ‘‘preset’’ size of organs, we are far from hav-
ing a clear picture of this basic question in developmental
biology. Nevertheless, investigations of the Hippo pathway on
organ size control have shed light into this mystery (Halder and
Johnson, 2011; Pan, 2010; Yu and Guan, 2013).
In 1995, two studies in Drosophila discovered that deletion of
Warts (wts) gene resulted in dramatic overgrowth of multiple tis-
sues (Justice et al., 1995; Xu et al., 1995). Several years later, a
flurry of studies showed that Salvador (sav) (Kango-Singh
et al., 2002; Tapon et al., 2002), Hippo (hpo) (Harvey et al.,
2003; Jia et al., 2003; Pantalacci et al., 2003; Udan et al., 2003;
Wu et al., 2003), and Mob as tumor suppressor (mats) (Lai
et al., 2005) mutant Drosophila phenocopy wts mutants with re-
gards to tissue overgrowth. Hpo, Sav, Wts, and Mats interact
genetically and physically, and the remarkable organ size pheno-
type elicited by their mutation is unprecedented in other estab-
lished developmental pathways; thus, they were grouped into
a new signaling module—the Hippo pathway—named after the
enormous size of hpo mutant organs, which resembles that of
a hippopotamus. Yorkie (yki), the key functional effector of the
Hippo pathway in organ size regulation, was soon discovered
in a screen for Wts-interacting proteins (Huang et al., 2005).
The Hippo pathway is highly conserved in mammals. The
mammalian orthologs of Hpo, Sav, Wts, Mats, and Yki are
Mammalian sterile 20-like 1/2 (MST1/2, also called STK4/3), Sal-
vador (SAV1), Large tumor suppressor homolog 1/2 (LATS1/2),
MOB kinase activator 1A/B (MOB1a/b), and Yes-associated pro-
tein (YAP)/transcriptional co-activator with PDZ binding motif
(TAZ, also called WWTR1), respectively (Halder and Johnson,
2011; Pan, 2010; Yu and Guan, 2013) (Table 1). The Hippopathway quickly attracted broad attention due to its remarkable
potency in regulating organ size, as well as its apparent rele-
vance to tissue regeneration and cancer. Here, with an emphasis
on recent developments, we review the current understanding of
the organization, regulation, and function of the Hippo pathway
and discuss some key open questions.
YAP/TAZ and Yki as Major Effectors of Hippo Signaling
In Drosophila, deleting yki suppresses the overgrowth pheno-
types of hpo, sav, or wts mutants (Huang et al., 2005). In
mice, deleting Yap also diminishes the overgrowth phenotypes
caused by deficiency of Mst1/2 or other upstream regulators
(Zhang et al., 2010; Zhou et al., 2011). Thus, Yki and YAP/TAZ
are the evolutionarily conserved key effectors of the Hippo
pathway.
Yki and YAP/TAZ are believed to mediate the biological func-
tions of the Hippo pathway by regulating gene transcription. As
transcriptional co-activators, Yki and YAP/TAZ cannot bind
DNA directly, and theymust interact with DNA-binding transcrip-
tion factors to regulate target gene expression. In Drosophila,
Scalloped (Sd) is a transcription factor and key partner of Yki
that mediates the function of Yki in tissue growth (Goulev
et al., 2008; Wu et al., 2008; Zhang et al., 2008; Zhao et al.,
2008). Similarly, in mammalian cells, the TEAD family transcrip-
tion factors (TEAD1–4, orthologs of Sd) are key partners for
YAP (Zhao et al., 2008). Several lines of evidence indicate that
TEADs are the major partners of YAP in transcriptional regula-
tion. For instance, a TEAD-binding-deficient YAP mutant lost
its ability to induce transcription of known YAP target genes
(Zhao et al., 2008), and knockin of the TEAD-binding-deficient
YAP (Y94A mutant) phenotypically mimics YAP knockout in the
skin and heart (Schlegelmilch et al., 2011; von Gise et al.,
2012). In addition, the majority of YAP and TEAD occupied sites
in the genome are shared (Stein et al., 2015; Zanconato et al.,
2015; Zhao et al., 2008), and when TEAD is fused with a VP16Cell 163, November 5, 2015 ª2015 Elsevier Inc. 811
Table 1. Hippo Pathway Components and Major Functions
Drosophila Mammals Major Functions in Hippo Pathway
Hippo (Hpo) MST1/2 Phosphorylates LATS1/2, MOB1, and SAV1, leading to LATS1/2 activation
Salvador (Sav) SAV1 Interacts with MST1/2, promotes phosphorylation of LATS1/2 by MST1/2
Warts (Wts) LATS1/2 Phosphorylates and inactivates YAP/TAZ
Mats MOB1A/B Scaffold protein of LATS1/2
Yorkie (Yki) YAP/TAZ Transcription co-activator, major effector of the Hippo pathway
Scalloped (Sd) TEAD1-4 Transcription factors that mediate the effect of YAP/TAZ
Tgi VGLL4 Competes with YAP/TAZ for TEADs, inhibits YAP/TAZ functions
misshapen (Msn) MAP4K4/6/7 Phosphorylates and activates LATS1/2
Merlin (Mer) Merlin/NF2 May form a complex and mediates upstream signals (from plasma membrane) to MST1/2;
NF2 may bring LATS1/2 to plasma membrane and facilitate its activation by MST1/2Kibra KIBRA
Expanded (Ex) FRMD6?
AMOT Sequesters YAP/TAZ to cell junctions, binding and indirectly activating LATS1/2;
a substrate of LATS1/2transactivation domain, it produces a gene expression profile
similar to that induced by active YAP (Ota and Sasaki, 2008).
TEAD1–4 or Sd can bind to a consensus motif similar to
the GTIIC sequence (TGGAATGT or ACATTCCA), and transcrip-
tion reporters under control of GTIIC concatemers are now
widely used to measure Hippo pathway activity (Dupont et al.,
2011; Mohseni et al., 2014; Ota and Sasaki, 2008). Besides
TEAD1–4, YAP/TAZ have also been shown to interact with other
transcription factors, including Smad, RUNX1/2, p63/p73, and
ErbB4 (reviewed in Varelas, 2014), although the functional signif-
icance of these transcription factors in Hippo pathway is less
clear.
A strong transcriptional activation domain is present in YAP/
TAZ but absent in Yki. Nevertheless, human YAP can rescue
the lethality resulting from Hippo pathway hyperactivation in
Drosophila, indicating a functional conservation (Huang et al.,
2005). Genome-wide assessment of chromatin binding status
reveals that, in addition to occupancy at proximal promoters of
target genes, YAP and TEAD largely exert their transcriptional
activity by interacting with distal enhancers, suggesting that
YAP, and probably TAZ and Yki, may regulate transcription via
multiple mechanisms, including recruitment of general transcrip-
tion factors, modification of epigenetic markers, and modulation
of chromatin structure (Lian et al., 2010; Stein et al., 2015; Zan-
conato et al., 2015) (Figure 1). Indeed, recent evidence shows
that Yki can interact with the Brahma complex, GAGA factors,
nuclear receptor coactivator 6 (NCoA6, a subunit of the Tri-
thorax-related histone methyltransferase), and the Mediator
complex (Jin et al., 2013; Oh et al., 2013; Qing et al., 2014),
and TAZ can interact with the chromatin-remodeling complex
SWI/SNF (Skibinski et al., 2014).
The transcriptional activity of Yki and YAP/TAZ is regulated in
the nucleus by Tondu-domain-containing growth inhibitor (Tgi)
and Vestigial-like family member 4 (VGLL4, an ortholog of Tgi).
Tgi can directly compete with Yki for Sd binding, resulting in in-
hibition of Yki-regulated transcription (Guo et al., 2013; Koontz
et al., 2013). When Hippo signaling is on, Tgi and Sd form a com-
plex, leading to transcriptional repression; on the contrary, when
Hippo signaling is off, Yki enters the nucleus and displaces Tgi812 Cell 163, November 5, 2015 ª2015 Elsevier Inc.from Sd, leading to expression of Yki target genes and tissue
growth (Koontz et al., 2013). In mammals, VGLL4 similarly com-
petes with YAP/TAZ for TEAD binding (Jiao et al., 2014; Zhang
et al., 2014b) (Figure 1). However, whether YAP/TAZ functions
simply by relieving a default repression of TEAD by VGLL4 has
not been demonstrated. Interestingly, the expression of VGLL4
appears to be repressed by miR-130a—a microRNA (miRNA)
that is directly induced by YAP, leading to amplification of YAP
activity (Shen et al., 2015). A similar mechanism is also present
in Drosophila, in which Bantam—a well-known Yki-induced
miRNA (Nolo et al., 2006; Thompson and Cohen, 2006), can
repress expression of Tgi (Shen et al., 2015).
Although their role as transcriptional co-activators is widely
appreciated, YAP/TAZ and Yki may also repress expression of
certain genes when bound to specific factors. For instance,
YAP/TAZ can interact with the nucleosome-remodeling and his-
tone deacetylase (NuRD) complex, resulting in transcriptional
repression (Kim et al., 2015). Moreover, YAP has been identified
as a regulator for global miRNA biogenesis via modulation of
miRNA-processing enzymes Microprocessor or Dicer complex,
suggesting a transcription-independent role for YAP (Chaulk
et al., 2014; Mori et al., 2014). Hence, YAP/TAZ and Yki may
regulate gene expression via multiple mechanisms.
Gene expression signatures under YAP/TAZ and Yki hyperac-
tivation (or ectopic expression) in Drosophila and different
mammalian cell types have been profiled by independent
studies. However, the overlap between these different gene
profiling studies is not high, suggesting that YAP/TAZ and Yki
may regulate target gene expression in a tissue- or cell-type-
specific manner. In Drosophila, some common Yki target genes
areBantam, diap1, and cyclin E, which maymediate the effect of
Yki in inhibiting cell death and promoting cell proliferation (Huang
et al., 2005; Nolo et al., 2006; Tapon et al., 2002; Thompson and
Cohen, 2006). In mammals, connective tissue growth factor
(CTGF) is a commonly used marker of YAP activation (Zhao
et al., 2008), and many genes involved in cell proliferation, cell
adhesion, and cell migration have also been identified as YAP
targets (Stein et al., 2015). It is likely that a panel of genes work
together to exert biological functions of YAP/TAZ.
Figure 1. Inhibition of YAP/TAZ Transcrip-
tional Coactivators by LATS1/2
(Left) When Hippo signaling is off, YAP/TAZ enter
the nucleus, compete with VGLL4 for TEADs, and
recruit other factors to induce gene transcription.
YAP/TAZ may bind proximal promoters or distal
enhancers of target genes to induce transcription.
(Right) When Hippo signaling is on, YAP/TAZ are
phosphorylated by LATS1/2 on multiple sites, re-
sulting in interaction with 14-3-3 and cytoplasmic
retention; phosphorylation also leads to YAP/TAZ
poly-ubiquitination and degradation. VGLL4 in-
teracts with TEADs and represses target gene
transcription.MST1/2 and LATS1/2 Kinases Restrict YAP Activity
In the Hippo pathway, LATS1/2 directly phosphorylate and
inhibit YAP/TAZ. Interestingly, YAP has five LATS1/2 target
consensus motifs (HXRXXS), four of which are conserved in
TAZ (Zhao et al., 2010). Phosphorylation of YAP on serine 127
(S127) generates a 14-3-3 binding site, and binding with
14-3-3 sequesters YAP in the cytoplasm (Dong et al., 2007;
Zhao et al., 2007). In addition, phosphorylation of YAP on serine
381 (S381) triggers a subsequent phosphorylation by casein ki-
nase 1 (CK1d/ε) and activation of a phosphodegron, resulting
in recruitment of SCFbeta-TRCP E3 ligase, ubiquitination, and pro-
teasomal degradation of YAP (Zhao et al., 2010). Thus, through
regulating both YAP subcellular localization and protein stability,
LATS1/2 ensures a spatial and temporal control of YAP activity
(Figure 1). TAZ is regulated by LATS1/2 in a similar fashion,
although degradation plays a more prominent role in TAZ
regulation possibly due to an additional phosphodegron at its
N terminus (Lei et al., 2008; Liu et al., 2010a). The subcellular
localization of Yki is regulated similarly by Wts phosphorylation
and 14-3-3 binding. However, the phosphodegron and the phos-
phorylation-mediated degradation mechanisms are not
conserved in Yki (Huang et al., 2005; Oh and Irvine, 2008). In
addition, YAP and Yki have also been shown to be degraded
via the autolysosomal pathway (Kwon et al., 2013; Liang et al.,
2014), suggesting a potential role of YAP and Yki in vesicular
membrane dynamics and related cellular processes such as
autophagy.
LATS1/2 are activated by MST1/2 through several mecha-
nisms. MST1/2 phosphorylate LATS1/2 at the C-terminal hy-
drophobic motif, which promotes LATS1/2 autophosphoryla-
tion at its activation loop. Furthermore, phosphorylation of
MOB1 by MST1/2 enhances MOB1 interaction with the autoin-
hibitory domain of LATS1/2, leading to full activation of LATS1/
2 (Callus et al., 2006; Chan et al., 2005; Praskova et al., 2004;
Wu et al., 2003). In addition, SAV1 is also phosphorylated by
MST1/2, and SAV1 functions as a partner of MST1/2 in pro-
moting LATS1/2 phosphorylation (Callus et al., 2006; TaponCell 163,et al., 2002) (Figure 1). In Drosophila,
Wts is regulated by Hpo, Sav, and
Mats by a similar mechanism (Wehr
et al., 2013).
Merlin (Mer), Expanded (Ex), and Kibra,
three cell-cortex-localized and cytoskel-
eton-interacting proteins, may functionas a scaffold for core Hippo components at the apical domain
for activation, as Sav, Hpo, and Wts have been shown to physi-
cally interact with Ex/Mer/Kibra (Baumgartner et al., 2010; Gen-
evet et al., 2010; Hamaratoglu et al., 2006; Yu et al., 2010) (Table
1). In addition, the effect of Ex/Mer/Kibra on the Hippo pathway
may be mediated by Tao kinase 1 (Tao-1), which can directly
phosphorylate and activate Hpo (Boggiano et al., 2011; Poon
et al., 2011). In mammalian cells, Neurofibromin 2 (NF2, Mer or-
tholog) appears to play a more direct role in regulating LATS1/2
activity: it can directly interact with LATS1/2 and recruit LATS1/2
to the plasma membrane for activation by MST1/2 (Yin et al.,
2013; Zhang et al., 2010) (Figures 2 and 3).
Hpo or MST1/2 are not absolutely required for regulation of
Wts or LATS1/2. It has been observed that, in mouse embryonic
fibroblast (MEF) cells, MST1/2 double knockout did not abolish
YAP phosphorylation, suggesting the existence of additional
Hippo-like activity (Zhou et al., 2009). Indeed, a recent study
in Drosophila has identified Misshapen (Msn) as another
kinase responsible for Wts activation. This mechanism is also
conserved in mammals, as MAP4K4 (Msn ortholog) overexpres-
sion promotes phosphorylation of LATS1/2 (Li et al., 2014), and
MAP4K4 knockdown induces activity of a YAP reporter (Moh-
seni et al., 2014). In addition to MAP4K4, two recent studies re-
vealed that many MAP4K family kinases, including MAP4K1/2/
3/5 (Happyhour in Drosophila) and MAP4K4/6/7 (Msn in
Drosophila), can directly phosphorylate and activate LATS1/2
(Meng et al., 2015; Zheng et al., 2015). These kinases, together
with MST1/2, may regulate LATS1/2 activity in a tissue- and
signal-specific manner. It is also possible that additional ki-
nases, especially some STE20 family members, may activate
LATS1/2 in response to different upstream signals or in different
tissue contexts (Figures 2 and 3).
YAP/TAZ have also been shown to be phosphorylated by
many other kinases such as cyclin-dependent kinase 1
(CDK1), Jun N-terminal kinases (JNK), homeodomain-interact-
ing protein kinases (HIPK), ABL, and Src family tyrosine kinases
(reviewed in Varelas, 2014), suggesting that YAP/TAZ can beNovember 5, 2015 ª2015 Elsevier Inc. 813
Figure 2. Regulation of the Hippo Pathway
in Drosophila
The Hippo pathway is regulated by cell-adhesion
molecules (Ed), determinants of cell polarity (Crb,
Fat/Ds, Scrib complex), and mechanical cues
(spectrin, F-actin, or cellular tension). In addition,
Hpo is regulated by Tao, salt-induced kinase (Sik),
Ras-associated factor (Rassf), striatin-interacting
phosphatase and kinase (STRIPAK) complex; Wts
is regulated by Zyxin (Zyx) and Jub; Yki is regu-
lated by WW-domain-binding protein 2 (Wbp2),
Hipk, and multiple ankyrin repeats single-KH
domain (Mask) (refer to Varelas, 2014). Arrows,
blunt ends, and dashed lines indicate activation,
inhibition, and indirect regulation, respectively.regulated by mechanisms independent of Hippo pathway ki-
nases.
Cell Polarity andCell AdhesionRegulate HippoSignaling
In searching for upstream regulators of the Hippo pathway,
many proteins involved in cell polarity and cell adhesion have
been identified. Echinoid (Ed), a cell adhesion molecule in
Drosophila, can interact with and stabilize Sav and leads to acti-
vation of Hpo (Yue et al., 2012). In mammalian cells, several pro-
teins at adherens and tight junctions, such as Angiomotin
(AMOT), protein tyrosine phosphatase non-receptor type 14
(PTPN14), and a-catenin, can sequester YAP/TAZ at cell junc-
tions (reviewed in Yu and Guan, 2013). Therefore, cell adhesion
and formation of intercellular junctions serve as a mechanism to
repress YAP/TAZ transcriptional activity (Figures 2 and 3).
Crumbs (Crb), a component of apical-basal polarity, interacts
with Ex, which is critical for the apical localization of Ex/Mer/
Kibra complex (Chen et al., 2010; Ling et al., 2010; Robinson
et al., 2010). In addition, Scribble (SCRIB) interacts with both
MST1/2 and LATS1/2, thus promoting LATS1/2 activation (Cor-
denonsi et al., 2011; Mohseni et al., 2014). Fat, a protocadherin
that plays a key role in planar cell polarity, also activates the
Hippo pathway, possibly through regulating Ex protein levels
and localization (Bennett and Harvey, 2006; Silva et al., 2006;
Tyler and Baker, 2007; Willecke et al., 2006) (Figure 2). However,
mammalian Fat orthologs do not seem to be major regulators of
the Hippo pathway (Sharma and McNeill, 2013). It is noteworthy
that the link between cell polarity and the Hippo pathway may be
indirect, and some proteins, such as Fat, may regulate cell po-
larity and Hippo signaling via different mechanisms (Matakatsu
and Blair, 2012).814 Cell 163, November 5, 2015 ª2015 Elsevier Inc.Cell Contact and Mechanical Cues
Regulate Hippo Signaling
Cells in solid tissues communicate with
neighboring cells and their extracellular
matrix (ECM) and perceive constant
physical signals from their local environ-
ment. Cell-cell contact was discovered
as the first signal regulating the Hippo
pathway (Zhao et al., 2007). In a sparse
culture, YAP/TAZ are primarily localized
in the nucleus to promote target gene
transcription and cell proliferation. Onthe contrary, at high cell density, YAP/TAZ are primarily cyto-
plasmic, corresponding to growth inhibition. It is known that a
cell ceases to proliferate following physical contact with sur-
rounding cells, and loss of cell contact inhibition is an indicator
of oncogenic transformation. Thus, regulation of YAP/TAZ by
cell density suggests a critical role for the Hippo pathway in con-
tact inhibition, tissue growth, and tumorigenesis.
Mechanical cues, such as ECM stiffness and cell geometry,
are also potent regulators of YAP/TAZ (Dupont et al., 2011)
(Figure 3). When cells are grown on a stiff matrix or are spread
across a large surface, YAP/TAZ are activated. In contrast,
when cells are seeded on a soft matrix or are compressed into
a small area, YAP/TAZ are inactivated. ECM stiffness and cell
geometry are important for cell proliferation and differentiation,
and YAP/TAZ activity plays a role in these cellular processes.
Cell geometry has also been proposed as a mechanism underly-
ing Hippo pathway regulation by cell density: at low density, cells
are flat and spread, leading to YAP activation; whereas at high
density, cells adopt a round and compact geometry, resulting
in YAP inactivation (Aragona et al., 2013; Wada et al., 2011).
As further support for a role of YAP/TAZ inmechanosensing, me-
chanical strain and shear stress have been shown to stimulate
YAP/TAZ, and YAP activation is required for mechanical strain-
induced cell-cycle reentry (Benham-Pyle et al., 2015; Codelia
et al., 2014; Kim et al., 2014). In a medaka fish model, YAP
also mediates changes in three-dimensional body shape in
response to tissue tension (Porazinski et al., 2015).
The attachment of cells to the ECM is an important mechanism
for maintaining cell survival, and cells normally undergo anoikis
when detached from the ECM. The attachment status of a cell
to its ECM can also regulate Hippo pathway activity. YAP is
Figure 3. Regulation of the Hippo Pathway
in Mammals
The Hippo pathway is regulated by diverse sig-
nals: (1) determinants of cell polarity and cell-cell
junctions, such as SCRIB, which interacts with
MST1/2 and LATS1/2, AMOT, PTPN14, and
a-catenin, which can sequester YAP/TAZ to cell
junctions; (2) mechanical cues, such as stiffness,
cell contact, cell geometry, and cell attachment
status that regulate the Hippo pathway by modu-
lating activity of Rho GTPases, remodeling the
actin cytoskeleton, or altering cellular tension;
both apical and basolateral spectrin networks may
function as sensors for mechanical cues in Hippo
pathway regulation; (3) soluble factors, especially
ligands for GPCRs, regulate LATS1/2 likely
through Rho GTPases and actin dynamics; (4)
metabolic status, such as cellular energy and
oxygen stress, also regulate Hippo signaling;
many other proteins such as protein phosphatase
2A (PP2A), protein phosphatase 1 (PP1), WBP2,
CDK1, MASK, and HIPK can also regulate activ-
ities of different Hippo pathway components (refer
to Varelas, 2014). Arrows, blunt ends, and dashed
lines indicate activation, inhibition, and indirect
regulation, respectively.activated during the process of cell attachment but inactivated
when cells are detached (Zhao et al., 2012). Expression of consti-
tutively active YAP promotes survival of detached cells, suggest-
ing that cancer cells with high YAP activity may escape anoikis
and undergo metastasis. In support of this notion, LATS1/2
expression was found to be selectively reduced in metastatic,
but not primary, prostate tumors (Zhao et al., 2012).
Soluble Factors Regulate Hippo Signaling
The primary function of YAP/TAZ is to promote growth, andmany
mitogenic hormones and growth factors act through G-protein-
coupled receptors (GPCR) to inducecell proliferation (Figure3). Li-
gands signal through GPCRs coupled to Ga12/13 or Gaq/11, such
as lysophosphatidic acid, thrombin, angiotensin II, and estrogen,
and can activate YAP/TAZ; in contrast, ligands signal through
Gas-coupled GPCRs and protein kinase A (PKA), such as
epinephrine and glucagon, can repress YAP/TAZ activity (Kim
et al., 2013; Miller et al., 2012; Mo et al., 2012; Wennmann et al.,
2014; Yu et al., 2013a; Yu et al., 2012; Zhou et al., 2015). Interest-
ingly, activationofproteinkinaseC (PKC)byGaq/11 caneitheracti-
vate or inhibit YAP, with conventional PKC activating YAP and
novel PKC inhibiting YAP (Gong et al., 2015). The remarkable dif-
ferential functions of PKC in YAP regulation provide amechanism
toexplain someof thecell-type-specific responses toPKCactiva-
tion.GPCR is the largest family ofmembrane receptorsmediating
diverse physiological or pathological responses. The demonstra-
tion of Hippo regulation by GPCRs links the Hippo pathway to a
wide range of upstream signals and biological functions.
The Wnt/b-catenin pathway is a key signaling cascade in
development and carcinogenesis. A destruction complex includ-
ing Axin, adenomatous polyposis coli (APC), and glycogen
synthase kinase-3 (GSK3) causes constant degradation of b-cat-
enin.Wnt stimulation disrupts the destruction complex and leads
to accumulation of b-catenin. Interestingly, recent studies sug-gest that YAP/TAZ are also activated by diverse Wnt family li-
gands. YAP/TAZ have been shown to be components of the
destruction complex and are regulated byWnt in a fashion similar
to that of b-catenin (Azzolin et al., 2012, 2014). However, a recent
study suggests thatWnt activatesYAP/TAZ viaFrizzled (aGPCR-
like Wnt receptor), Ga12/13, Rho GTPases, and LATS1/2 (Park
et al., 2015). In addition, APC has been shown to act as a scaffold
protein for SAV1 and LATS1, and Apc deletion leads to YAP acti-
vation and tumorigenesis (Cai et al., 2015). More studies may be
needed to verify the mechanism of YAP/TAZ activation by Wnt.
Epidermal growth factor (EGF) and insulin have also been
shown to regulate YAP/Yki activity in cultured mammalian cells
and Drosophila, and these signals are mediated by the Ras-Raf-
MAPK signaling cascade or phosphoinositide-dependent kinase
(PDK1) (Fan et al., 2013; Reddy and Irvine, 2013; Straßburger
et al., 2012). TAZ is also stabilized upon PI3K activation, which
is mediated by direct phosphorylation by GSK3 (Huang et al.,
2012). However, no significant effect of EGF and IGF on YAP
was observed in several other studies, and YAP activity appeared
tobenormal in thepresenceof inhibitorsofPI3KorAKTor inPDK1
null embryonic cells (Yu et al., 2012; Zhao et al., 2007). These dis-
crepancies could bedue to differences in experimental settings or
cell types and should be clarified by future studies.
Effect of Cellular Metabolic Status on Hippo Signaling
Recently, a link between cellular metabolic status and the
Hippo pathway has been reported (Figure 3). Under energy
deprivation, such as glucose starvation, the AMPK-activated
protein kinase (AMPK) can directly phosphorylate YAP at serine
61 (S61) and serine 94 (S94) (Mo et al., 2015; Wang et al., 2015).
Phosphorylation of YAP S94 abolishes the interaction between
YAP and TEADs, leading to inhibition of YAP activity. In addition,
energy stress also inhibits YAP by increasing kinase activity
of LATS1/2 either in an AMPK-dependent or -independentCell 163, November 5, 2015 ª2015 Elsevier Inc. 815
manner (Mo et al., 2015; Wang et al., 2015). AMPK can phos-
phorylate AMOTL1, which in turn facilitates YAP phosphorylation
by LATS1/2 (DeRan et al., 2014). A similar mechanism is also
present in Drosophila, in which Ampk inactivates Yki and affects
cell proliferation in the larval central brain and central nerve cord
(Gailite et al., 2015). It appears that, during energy stress, both
AMPK and LATS1/2 are unleashed to restrict YAP activity. These
findings also suggest that the Hippo pathway may mediate the
anticancer effect of metformin, which is known to activate
AMPK (DeRan et al., 2014; Mo et al., 2015). Other than AMPK,
glucose may also promote YAP/TAZ activity through phospho-
fructokinase, which stimulates the interaction between YAP/
TAZ and TEADs (Enzo et al., 2015).
YAP/TAZ activity has also been linked to oxygen availability.
Under hypoxic conditions, the hypoxia-inducible factor 1 (HIF1)
stimulates expression of SIAH1/2, two E3 ubiquitin ligases.
SIAH1/2 then promote ubiquitination and degradation of
LATS2, leading to YAP/TAZ activation (Ma et al., 2015; Xiang
et al., 2014) (Figure 3). In addition, HIF1 directly induces tran-
scription of TAZ (Xiang et al., 2014), and YAP interacts with
and stabilizes HIF1 to enhance transcription of HIF1 target genes
(Ma et al., 2015).
YAP/TAZ are potent stimulators of cell growth and pro-
liferation, which are energy-consuming processes. The regu-
lation of Hippo signaling by AMPK suggests that metabolic
status can function as a checkpoint for growth-promoting
activity of YAP/TAZ. Under conditions of nutrient deprivation
or energy crisis, YAP/TAZ activity needs to be restricted to
prevent energy exhaustion caused by anabolic processes.
Oxygen also plays a critical role in cellular metabolism, and hyp-
oxia is involved in different pathological processes such as can-
cer. The link between hypoxia and YAP/TAZ activity indicates a
role of YAP/TAZ in mediating oncogenic effect of hypoxia.
Actin Cytoskeleton Integrates Upstream Signals
The actin cytoskeleton and Rho GTPases are not only important
in maintaining cell morphology, but also play important roles in
regulating cell proliferation and differentiation (Jaffe and Hall,
2005). Manipulation of the actin cytoskeleton, such as overex-
pressionofRhoGTPasesor inhibition ofRhobyC3 toxin, dramat-
ically modulates YAP/TAZ activity (Dupont et al., 2011; Yu et al.,
2012; Zhao et al., 2012). RhoGTPases and changes in actin cyto-
skeleton dynamics have been demonstrated to be keymediators
of mechanical cues, GPCR ligands, and cell attachment in regu-
lating the Hippo pathway (Figure 3). Consistently, deletion of
different regulators of the actin cytoskeleton impacts YAP and
Yki activity. For instance, loss of actin-capping proteins or the
Capulet gene (which inhibits actin polymerization) in Drosophila
results in Yki activation and tissue overgrowth (Ferna´ndez et al.,
2011; Sansores-Garcia et al., 2011). Similarly, knockdown of
actin-capping proteins or filamentous actin (F-actin)-severing
proteins (cofilin or gelsolin) in mammalian cells also leads to
YAP activation (Aragona et al., 2013). In general, RhoGTPase ac-
tivity and F-actin appear to activate YAP/TAZ, whereas destabi-
lization of F-actin inhibits YAP/TAZ (Dupont et al., 2011; Miller
et al., 2012; Wada et al., 2011; Yu et al., 2012; Zhao et al., 2012).
Spectrin proteins, in association with short actin filaments, are
organized into an elastic polygonal meshwork that lines the intra-816 Cell 163, November 5, 2015 ª2015 Elsevier Inc.cellular side of the plasmamembrane. In epithelial cells, localiza-
tion of the spectrin network is usually polarized and present in
both apical and basolateral domains. In addition to a supporting
role for cell structure, the spectrin network may transmit diverse
signals from cell microenvironment to regulate cellular functions
(Bennett and Gilligan, 1993). Recently, three independent
studies revealed a regulatory role of the spectrin network on
the Hippo pathway, as disruption of the spectrin network in mul-
tiple Drosophila tissues leads to activation of Yki and tissue
outgrowth (Deng et al., 2015; Fletcher et al., 2015; Wong et al.,
2015). A similar phenomenon was also observed in mammalian
cells to support a role of spectrin in YAP regulation (Figures 2
and 3). Therefore, spectrins or associated actin filaments may
function as a major node for integrating upstream signals, such
as mechanical cues.
Despite its apparent importance, it remains unclear how the
actin cytoskeleton regulates activity of Hippo pathway core ki-
nases. One possibility is that multiple Hippo pathway compo-
nents are enriched at the apical domain via an actin-mediated
mechanism that facilitates signal transduction, and actin remod-
eling may reinforce or disrupt the clustering of Hippo pathway
components. In another scenario, the Hippo pathway could
be regulated by contractile actomyosin and cellular tension
(Figure 3). Inhibition of tension-related enzymes, such as non-
muscle myosin (by Blebbistatin), Rho kinases (ROCK, by
Y27632), and myosin light-chain kinase (by ML-7), results in
YAP/TAZ inhibition (Dupont et al., 2011;Wada et al., 2011). How-
ever, how tension is sensed by the Hippo pathway kinases is not
fully understood. Treating cells with small molecules to inhibit
cellular tension may also affect actin dynamics, so it is difficult
to separate the effects of actin remodeling and tension gener-
ated by actomyosin. However, it has been proposed that, in
Drosophila, Ajuba (Jub) plays a critical role in tension-induced
Yki regulation. In response to high tension, Jub recruits Wts to
intercellular junctions via interactions with a-catenin, thereby in-
hibiting Wts activity (Rauskolb et al., 2014). In addition, JNK acti-
vation upon mechanical strain has also been shown to repress
LATS1 (Codelia et al., 2014).
Although it has been initially reported that YAP regulation by
mechanical signals is independent of LATS1/2, recent studies
suggest that LATS1/2 are involved in YAP/TAZ regulation by
the actin cytoskeleton (Miller et al., 2012; Wada et al., 2011; Yu
et al., 2012; Zhao et al., 2007, 2012). This discrepancy may be
due to incomplete LATS1/2 depletion in knockdown experi-
ments reported in earlier studies. Supporting a role for
LATS1/2, the phosphorylation status and in vitro kinase activity
of LATS1/2 are clearly regulated upon actin cytoskeleton rear-
rangement, and the kinetics are similar to that of YAP/TAZ phos-
phorylation (Yu et al., 2012; Zhao et al., 2012). The regulation of
Yki/YAP/TAZ by spectrins or cell attachment/detachment has
been shown to be dependent on Wts and LATS1/2 (Deng
et al., 2015; Fletcher et al., 2015; Zhao et al., 2012). Moreover,
during the preimplantation stage of mouse embryo develop-
ment, LATS1/2 are essential for YAP regulation by small
molecules targeting the actin cytoskeleton (Kono et al., 2014).
Collectively, mechanical signals most likely act through Wts
and LATS1/2 to influence the activity and function of Yki and
YAP/TAZ.
Negative Feedback Regulation and Crosstalk
High Yki or YAP/TAZ activity, especially over the long term, re-
sults in tissue overgrowth or cancer (see below). Thus, the phys-
iological fluctuation of Hippo signaling must be tightly controlled
to avoid detrimental effects. In Drosophila, regulation of the
Hippo pathway is fine-tuned by a built-in negative-feedback
loop in which activation of Yki turns on the expression of up-
stream regulators, including Four-jointed, Ex, Mer, Kibra, and
Wts (Cho et al., 2006; Genevet et al., 2010; Hamaratoglu et al.,
2006; Jukam et al., 2013). Consistently, a similar negative feed-
back mechanism also exists in mammalian cells. YAP/TAZ
directly induce the transcription of NF2, LATS2, and probably
MST1, leading to LATS1/2 activation and YAP/TAZ inhibition
(Chen et al., 2015b; Dai et al., 2015; Moroishi et al., 2015b). In
addition, YAP/TAZ induce expression of angiomotin-like protein
2 (AMOTL2), a negative regulator of YAP (Mohseni et al., 2014;
Zhao et al., 2008). This negative feedback loop is critical for
maintaining the proper transient activation of YAP/TAZ upon
stimulation. By these mechanisms, YAP and TAZ antagonize
each other and may provide a buffer for fluctuations in Hippo
pathway activity to ensure tissue homeostasis. When this nega-
tive feedback is disrupted, dysregulation of the Hippo pathway
may lead to tumorigenesis.
Elucidating the Hippo pathway regulation and function is
complicated by crosstalk between the Hippo pathway and
many other developmental signaling pathways (reviewed in Var-
elas, 2014). Besides Wnt, YAP/TAZ may also be regulated by
sonic hedgehog (SHH) signaling (Fernandez-L et al., 2009). On
the other hand, YAP/TAZ has been shown to regulate the ex-
pression of ligands for Wnt, Shh, transforming growth factor b
(TGF-b), JAK-STAT, EGFR, and Notch pathways (reviewed in
Yu et al., 2015). The extensive signaling crosstalk may create a
microenvironment rich in different factors, which in turn regulates
cell fate through autocrine or paracrine mechanisms in both cell-
autonomous and cell-non-autonomous manners.
Hippo Pathway in Early Embryonic Development
YAP/TAZ are critical during early embryonic development.
Although TAZ knockout mice are viable, YAP knockout mice
die at E8.5, and blastomeres stop dividing before the morula
(16–32 cells) stage when YAP and TAZ are both deleted (Hossain
et al., 2007; Makita et al., 2008; Morin-Kensicki et al., 2006; Nish-
ioka et al., 2009; Tian et al., 2007). Therefore, the role of YAP/TAZ
in early development is partially overlapping.
The first cell fate specification during embryogenesis occurs
during preimplantation stage, in which the trophectoderm (TE)
and inner cell mass (ICM) are formed. The TE consists of the
outer cells of the blastocyst and forms extraembryonic tissues,
while the ICM contains the inner cells of the blastocyst and
give rise to the embryo proper and other tissues. The formation
of the TE and ICM is mainly due to the position or polarity of cells
in the morula, in which the inner and apolar cells form the ICM,
while the outer and polar cells give rise to the TE (Sasaki,
2015). As early as the 16-cell stage, YAP/TAZ already show dif-
ferential subcellular localization between inner and outer cells,
and this difference lasts to the blastocyst stage. The different
distribution of YAP/TAZ in the TE and ICM results in different
gene expression signatures, especially the induction of TE-spe-cific genes, such as Cdx2 in outer cells, thus directing cell fate
specification (Nishioka et al., 2009). Indeed, mouse embryos
with TEAD4 knockout failed to develop TE cells, with all cells
differentiating into ICM. On the other hand, depleting LATS1/2,
NF2, or AMOT/AMOTL2 turns all cells into TE linage, and these
embryos failed to develop ICM-derived tissues (Cockburn
et al., 2013; Hirate et al., 2013; Lorthongpanich et al., 2013).
These results suggest that the Hippo pathway plays a key role
in early embryonic cell specification.
Hippo Signaling in Organ Size Control and Tissue
Homeostasis
The effect on organ size is the best-known physiological function
of the Hippo pathway. In Drosophila, mutation of Hippo pathway
kinases (hpo and wts) or upstream regulators (ex, mer, kibra,
ft, etc.) leads to overgrowth of organs such as eyes, wings, or
other appendages, and transgenic expression of yki results in a
similar phenotype (reviewed in Halder and Johnson, 2011; Pan,
2010). The increased tissue/organ size is mainly due to Yki-
induced cell proliferation and survival.
The effect of the Hippo pathway on organ size is highly
conserved in mammals, as revealed by many studies performed
in mice (summarized in Table 2). For instance, liver-specific
transgenic Yap expression in mice can produce a dramatically
enlarged liver. Remarkably, the liver returns to its normal size
via apoptosis once Yap overexpression is turned off (Camargo
et al., 2007; Dong et al., 2007). Similarly, liver-specific knockout
ofMst1/2,Sav1, orNf2 also results in liver enlargement (Yin et al.,
2013; Zhang et al., 2010; Zhou et al., 2009). The mouse embry-
onic heart is enlarged when Sav1,Mst1/2, or Lats1/2 is deleted,
and proliferation or apoptosis of cardiomyocytes is sensitive to
genetic manipulation of Yap (Del Re et al., 2013; Heallen et al.,
2011; Lin et al., 2014; von Gise et al., 2012; Xin et al., 2013; Xin
et al., 2011).
However, not all organs are equally sensitive to Hippo pathway
mutations. For instance, Mst1/2 knockout results in dramatic
overgrowth of liver, heart, stomach, and spleen, but not of kid-
ney, lung, or limbs (Song et al., 2010). A possible explanation is
that there are MST1/2-independent regulators of YAP/TAZ in
these tissues. In the breast and intestine, tissue-specific deletion
of Yap does not result in any defects in tissue structure or size
(Cai et al., 2010; Chen et al., 2014). Yap knockout in the mouse
liver leads to bile duct defects, but not a general reduction of liver
size. This lack of effect could be due to the presence of TAZ,
which should be activated due to the loss of feedback inhibition
upon Yap deletion. Alternatively, the Hippo pathway, or YAP/TAZ
activity, may be negligible for the size control of some organs.
Nevertheless, the organ-specific effects of the Hippo pathway
in size control may suggest that different principles are utilized
for size regulation in different organs. For example, organ size
could be determined by proliferation of differentiated cells or
the number of progenitor cells in a pre-allocated pool.
Physiological signals upstream of the Hippo pathway impor-
tant in organ size determination have yet to be identified.
Mechanical force or tension may change as a result of organ
growth andmay inhibit YAP/TAZ when the organ reaches its final
size. Alternatively, organ size may be restricted/induced by a
soluble factor via autocrine/paracrine mechanisms, and theCell 163, November 5, 2015 ª2015 Elsevier Inc. 817
Table 2. Physiological and Pathological Functions of Hippo Pathway Genes in Mice
Organ Phenotypes References
Liver Yap-inducible expression results in hepatomegaly in a reversible
manner and, in long term, leads to development of liver tumors.
Camargo et al., 2007; Dong et al., 2007
Nf2, Sav1, or Mst1/2 deletion causes hepatomegaly and results
in hepatocellular carcinoma, cholangiocarcinoma, or bile duct
hamartoma. Mob1a/b deletion also causes liver cancer.
Benhamouche et al., 2010; Lee et al., 2010;
Lu et al., 2010; McClatchey et al., 1998;
Nishio et al., 2012; Song et al., 2010; Yin et al.,
2013; Zhang et al., 2010; Zhou et al., 2009
Yap deletion causes bile duct defect, and YAP activity is involved
in liver regeneration upon tissue damage.
Bai et al., 2012; Su et al., 2015; Yimlamai et al.,
2014; Zhang et al., 2010
Lkb1-deficiency-induced liver overgrowth is dependent on YAP
activation.
Mohseni et al., 2014
Intestine Yap transgenic expression causes intestinal dysplasia. Camargo et al., 2007
Deletion of Sav1 or Mst1/2 in mouse intestine results in expansion
of progenitor cells, colonic polyps, or adenoma.
Cai et al., 2010; Lee et al., 2008; Zhou et al.,
2011
Deletion of Yap in mouse intestine shows no obvious phenotype
but affects regeneration upon tissue damage.
Cai et al., 2010
Yap transgenic expression (intestine specific) results in rapid loss
of intestinal crypts by repressing Wnt signaling.
Barry et al., 2013
Apc-deletion-induced expansion of intestinal crypts in a YAP/TAZ-
dependent manner.
Azzolin et al., 2014; Cai et al., 2015
Skin Deletion of Sav1 or transgenic expression of Yap leads to
expansion of basal progenitor cells and skin thickening;
long-term activation of YAP results in squamous cell carcinoma.
Mob1a/b deletion also causes skin cancer.
Camargo et al., 2007; Lee et al., 2008;
Nishio et al., 2012
Deletion of Mst1/2 shows no clear phenotype. Deletion of Ctnna1
(a-Catenin) leads to keratinocyte hyperproliferation and squamous
cell carcinoma likely mediated by YAP activation.
Schlegelmilch et al., 2011
Gnas (Gs) deletion causes basal-cell carcinoma partially
dependent on YAP activation.
Iglesias-Bartolome et al., 2015
Heart Deletion of Sav1, Mst1/2, or Lats2 at embryonic stage or
transgenic expression of active Yap mutant results in
hyperproliferation of cardiomyocytes and enlargement of heart.
Del Re et al., 2013; Heallen et al., 2011;
Lin et al., 2014; von Gise et al., 2012;
Xin et al., 2013; Xin et al., 2011
Deletion of Yap leads to heart hypoplasia, and more severe
phenotype is observed when both Yap and Taz are deleted.
von Gise et al., 2012; Xin et al., 2011
In adult heart, high YAP/TAZ activity enhances heart
regeneration following cardiac damages such as myocardial
infarction.
Heallen et al., 2013; Lin et al., 2014;
Xin et al., 2013
Kidney Taz deletion causes polycystic kidney disease, whereas Yap
deletion leads to hypoplastic kidneys with severe defect in
nephron morphogenesis.
Hossain et al., 2007; Makita et al., 2008;
Reginensi et al., 2013; Tian et al., 2007
Kidney with Mst1/2 or Sav1 deletion appears normal. Reginensi et al., 2013; Song et al., 2010
Lung Taz-deleted mice display abnormal alveolar structures. Makita et al., 2008; Mitani et al., 2009;
Tian et al., 2007
Mst1/2 deletion leads to disrupted lung structures and neonatal
lethality, which is dependent on high YAP/TAZ activity. Mst1/2
deletion in adult lung bronchiolar epithelial cells results in airway
hyperplasia and altered differentiation. YAP appears critical in
regulating proximal-distal patterning of the lung, and a
decrease in YAP activity ensures epithelial cells differentiation.
Lange et al., 2015; Lin et al., 2015a;
Mahoney et al., 2014
Mob1a/b deletion causes lung tumor. Nishio et al., 2012
Forkhead box A2 (FOXA2) has also been shown critical in
mediating the effect of Mst1/2 in lung development.
Chung et al., 2013
(Continued on next page)
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Table 2. Continued
Organ Phenotypes References
Pancreas The effect of Hippo pathway is mainly in the exocrine compartment
of the pancreas. During postnatal stage, deletion of Mst1/2 increases
the ratio of ductal and acinar cells and leads to pancreatitis-like
autodigestion and a reduced size of pancreas.
Gao et al., 2013; George et al., 2012
Kras (K12D)-mutant-induced pancreatic ductal adenocarcinoma
requires YAP activity.
Zhang et al., 2014a
Nervous System Nf2 deletion causes an expansion of the neural progenitor pool
and results in enlargement of the cortical hem, malformation of
hippocampus (at late embryogenesis), and thickening of the
neurocortex. Nf2 deletion also affects development of corpus
callosum, in which Yap-mediated overexpression of SLIT2
disrupts callosal axon pathfinding.
Lavado et al., 2013; Lavado et al., 2014
Mammary glands Yap and Sav1 are dispensable in mammary glands development.
During pregnancy, Yap deletion results in hypoplasia and reduced
alveolar structures; on the other hand, Sav1 deletion or
transgenic expression of Yap prevents terminal differentiation
of mammary cells.
Chen et al., 2014
Mob1a/b deletion causes breast tumor. Nishio et al., 2012
Yap deletion delays mammary tumor growth induced by polyoma
middle T antigen (PyMT).
Chen et al., 2014
Muscle Yap overexpression promotes proliferation of satellite cells and
represses their differentiation. YAP downregulation reduces basal
skeletal muscle fiber size, and YAP activity is required to relieve
neurogenic muscle atrophy following injuries.
Judson et al., 2012; Watt et al., 2015concentration of this factor is controlled by organ size. These two
models are not mutually exclusive, and further investigations are
needed to address how the Hippo pathway senses physiological
cues to modulate organ size.
High YAP/TAZ activity has been observed in the stem or pro-
genitor cells of multiple tissues, suggesting a role for YAP/TAZ in
stem cell maintenance. For example, YAP is highly nuclear in
basal progenitor cells and in intestinal stem cells localized at
the crypt base (Barry et al., 2013; Camargo et al., 2007; Schlegel-
milch et al., 2011; Zhang et al., 2011). Activation of YAP, either by
transgenic expression of YAP or deletion of upstream regulators,
usually results in expansion of progenitor cells, impaired cell dif-
ferentiation, and hyperplasia of target tissues such as intestine,
liver, skin, and nervous system (Cai et al., 2010; Camargo
et al., 2007; Cao et al., 2008; Lee et al., 2008, 2010; Lu et al.,
2010; Zhou et al., 2011).
The role of YAP/TAZ on cell proliferation and stem cell expan-
sion suggests a critical function of YAP in normal tissue develop-
ment and homeostasis. Indeed, tissue-specific deletion of Yap
results in abnormalities of the heart, skin, and kidney (Reginensi
et al., 2013; Schlegelmilch et al., 2011; von Gise et al., 2012; Xin
et al., 2011). However, mammary glands and the intestine remain
relatively normal upon Yap deletion (Cai et al., 2010; Chen et al.,
2014; Zhou et al., 2011). These findings suggest that YAP is
required for development and homeostasis of some, but not
all, tissues in mice. In human, TEAD1 mutations are found in
Sveinsson chorioretinal atrophy, a disease characterized by
chorioretinal degeneration, and Aicardi syndrome, a congenital
neurodevelopmental disorder (Fossdal et al., 2004; Schrauwen
et al., 2015). In addition, loss-of-function mutations of YAPhave been identified in both isolated and syndromic optic fissure
closure defects (Williamson et al., 2014). Hence, the loss of
TEAD-mediated YAP transcriptional activity plays a role in
some degeneration-related disorders in humans.
Even though it is not required for development and normal ho-
meostasis of some tissues, YAP activity is critical for tissue
regeneration upon certain types of damage. For example, Yap
deletion severely compromises pregnancy-induced mammary
tissue growth, although virgin mammary development was
normal (Chen et al., 2014). Likewise, in wild-type mice, the intes-
tines can effectively regenerate following colitis induced by
dextran sulfate sodium (DSS) treatment; however, the regenera-
tive capability is severely impeded in conditional Yap knockout
mice (Cai et al., 2010). Similar results have also been observed
in Drosophila midgut regeneration upon DSS-induced injury
(Karpowicz et al., 2010; Ren et al., 2010; Shaw et al., 2010). Nor-
mally the liver regenerates efficiently following liver damage. For
instance, after partial hepatectomy, hepatocytes start to prolifer-
ate to restore liver mass in a few days, and in this process, YAP
activity is induced and is most likely required for complete liver
regeneration (Grijalva et al., 2014; Su et al., 2015; Wu et al.,
2013; Yimlamai et al., 2014). In contrast to the intestine and liver,
tissue regeneration of the adult heart is very limited. However,
inactivation of the Hippo pathway or transgenic expression of
Yap restores some myocardial regenerative capability, although
the efficiency is low. In contrast, cardiac-specific deletion of Yap
impedes regeneration of the neonatal heart (Heallen et al., 2013;
Lin et al., 2014; Xin et al., 2013). Taken together, these results
indicate that YAP plays a significant role in regeneration of mul-
tiple tissues.Cell 163, November 5, 2015 ª2015 Elsevier Inc. 819
Hippo Signaling in Cancer
Long-term YAP activation, such as transgenic expression of Yap
in the mouse liver, results in cell transformation and tumor devel-
opment (Dong et al., 2007), indicating the power of the Hippo
pathway in cancer initiation and progression. Evidence of the
Hippo pathway in tumorigenesis based on mouse models is
summarized in Table 2, which generally supports an oncogenic
role for YAP/TAZ, as well as a tumor-suppressive function for
Hippo pathway upstream components.
The tumor-promoting activity of YAP is largely dependent on a
TEAD-mediated transcription program, as YAP-induced liver
cancer is fully blocked by expression of a dominant-negative
TEAD that is able to sequester both YAP and TAZ (Liu-Chitten-
den et al., 2012). At the cellular level, YAP activation is important
for cell proliferation, survival, migration, and invasion. High YAP
or TAZ activity enables the cell to escape contact inhibition and
anoikis and to support anchorage-independent growth (Chan
et al., 2008; Zhao et al., 2007, 2012). YAP induces expression
of ZEB1/2 to stimulate the epithelial-to-mesenchymal transition
(EMT), which is a key step for tumor metastasis (Gao et al.,
2014; Lei et al., 2008; Liu et al., 2010b; Overholtzer et al.,
2006). In addition, YAP is able to promote genomic instability
(Fernandez-L et al., 2012), and TAZ is required to sustain self-
renewal and the tumor-initiation capacity of breast cancer
stem cells (Cordenonsi et al., 2011).
Accumulating evidence suggests that the Hippo pathway is
dysregulated in many human cancers. Elevated YAP/TAZ ex-
pression or nuclear enrichment of YAP/TAZ has been observed
in many types of cancers, including liver, breast, lung, colon,
ovary, and others (Chan et al., 2008;Moroishi et al., 2015a; Stein-
hardt et al., 2008). However, the majority of cancers with high
YAP/TAZ activity have not been linked to genetic mutations of
the Hippo pathway, and the overall genetic alteration rate of
Hippo pathway components in human cancer is relatively low
(Table 3).
One well-characterized example of a Hippo pathway mutation
associated with cancer is in NF2, which causes neurofibroma-
tosis 2 lesions, including schwannomas and meningiomas (Xiao
et al., 2003). Moreover, inactivating NF2 mutations are also
observed in 40%–50% of malignant mesothelioma (Sekido,
2011). Importantly, evenheterozygousdeletionofYapcompletely
blocks liver tumorigenesis induced byNf2 knockout in mice, indi-
cating that YAP activation is the major mechanism mediating the
tumorigenic potential of Nf2mutations (Zhang et al., 2010).
YAP gene amplification may contribute to a portion of hepato-
cellular carcinomas, medulloblastomas, and esophageal squa-
mous cell carcinomas (Fernandez-L et al., 2009; Overholtzer
et al., 2006; Song et al., 2014; Zender et al., 2006). Gene fusions
involving YAP or TAZ have also been discovered in human can-
cers. Remarkably, virtually all epithelioid hemangioendothelio-
mas contain gene fusions of TAZ-CAMTA1, TAZ-FOSB, or
YAP-TFE3 (Antonescu et al., 2013; Errani et al., 2011; Flucke
et al., 2014; Tanas et al., 2011). In addition, YAP gene fusions
with MAMLD1 or C11orf95 have been discovered in a subset
of ependymal tumors (Pajtler et al., 2015; Parker et al., 2014). It
is worth noting that, in both epithelioid hemangioendotheliomas
and ependymal tumors, all YAP/TAZ fusion proteins retain their
N-terminal TEAD-binding domain but lose the C-terminal trans-820 Cell 163, November 5, 2015 ª2015 Elsevier Inc.activation domain. These observations suggest that these YAP
fusions may still bind to and activate the TEAD-dependent tran-
scriptional program to promote tumorigenesis. Indeed, neural
stem cells carrying the YAP-C11orf95 fusion gene can effectively
form brain tumors when grafted into mice (Parker et al., 2014). In
addition, a familial YAP point mutation (R331W) has also been re-
ported to correlate with a high incidence of lung adenocarci-
nomas (Chen et al., 2015a).
Aberrant GPCR signaling often results in tumorigenesis, so it is
possible that GPCR dysregulation can cause cancer by acti-
vating YAP/TAZ. GNAQ- or GNA11- (encoding Gaq or Ga11,
respectively) activating mutations have been identified in 80%
of uveal melanomas and function as driver mutations (Van
Raamsdonk et al., 2009; Van Raamsdonk et al., 2010). Recent
studies showed that YAP is constitutively activated in GNAQ-
or GNA11-mutated uveal melanomas, and the high YAP activity
contributes to tumor growth (Feng et al., 2014; Yu et al., 2014).
In mice, deletion of Gnas (encoding GaS) in skin stem cells initi-
ates basal-cell carcinogenesis, which is partially dependent on
YAP (Iglesias-Bartolome et al., 2015). Moreover, expression of
a viral GPCR induces tumorigenesis in Kaposi’s sarcoma, where
YAP/TAZ also play a critical role (Liu et al., 2015).
LATS1/2 mutations or gene fusion have been sporadically
identified in different cancers, which may lead to YAP/TAZ
activation (Table 3). In addition, crosstalk with other cancer-
related signaling pathways also likely contributes to high
YAP/TAZ activity in cancers that have no mutations of Hippo
pathway components. For example, KRAS, APC, and LKB1
mutations have all been reported to activate YAP/TAZ (Azzolin
et al., 2014; Gao et al., 2014; Mohseni et al., 2014; Zhang
et al., 2014a).
YAP/TAZ activity is also linked to drug resistance and cancer
relapse. Cultured breast cancer cells with high YAP/TAZ activity
show resistance to drugs such as taxol, 5-fluorouracil, and doxo-
rubicin (Cordenonsi et al., 2011; Lai et al., 2011; Touil et al.,
2014). Furthermore, lung and colon cancer cells with high YAP
activity are resistant to RAF- and MEK-targeted therapies (Lin
et al., 2015b). Tamoxifen is commonly used to treat estrogen-re-
ceptor- (ER, a nuclear receptor) positive breast cancer; however,
some ER-positive breast cancers are insensitive to tamoxifen.
Recently, tamoxifen has been shown to activate YAP/TAZ by
stimulating the membrane estrogen receptor GPER, a GPCR.
Therefore, activation of GPER by tamoxifen or estrogen may
contribute to tumor growth and drug resistance (Zhou et al.,
2015). Amplification of the YAP gene has been associated with
cancer relapse in KRAS-driven colon and pancreatic cancers
(Kapoor et al., 2014; Shao et al., 2014). Thus, inhibition of YAP/
TAZ will not only target tumor initiation and progression, but
also potentially sensitize cancer cells to chemotherapies and
prevent cancer relapse.
Notably, in contrast to its oncogenic function in most solid
tumors, YAP seems to play a tumor-suppressor role in hemato-
logical cancers. The YAP gene locus is frequently deleted in he-
matological cancer, and expression of YAP or inhibition of MST1
leads to growth inhibition and increased apoptosis (Cottini et al.,
2014). Currently, the underlying mechanism responsible for this
tumor-suppressor function of YAP in hematological cancers is
not well understood.
Table 3. Genetic Alterations of Hippo Pathway Genes in Human Cancers
Gene Alteration Cancer type References
NF2 mutation or deletion mesothelioma
neurofibromatosis type 2 (schwannoma,
meningioma)
Sekido, 2011
Rouleau et al., 1993
LATS1/2 gene fusion
(LATS1-PSEN1)
mesothelioma Miyanaga et al., 2015
LATS2 deletion mesothelioma Murakami et al., 2011
LATS1/2 mutations sporadic in different cancers Yu et al., 2013b
YAP amplification hepatocellular carcinoma
medulloblastoma
esophageal squamous cell carcinoma
Fernandez-L et al., 2009
Overholtzer et al., 2006
Song et al., 2014
Zender et al., 2006
mutation (R331W) lung adenocarcinoma Chen et al., 2015a
gene fusion
(YAP-TFE3, YAP-ESR1, YAP-
C11orf95, and YAP-MAMLD1)
epithelioid hemangioendothelioma
luminal breast cancer
ependymal tumors
Antonescu et al., 2013
Flucke et al., 2014
Li et al., 2013
Pajtler et al., 2015
Parker et al., 2014
deletion hematological cancer Cottini et al., 2014
TAZ gene fusion
(TAZ-CAMTA1 and TAZ-FOSB)
epithelioid hemangioendothelioma Errani et al., 2011
Flucke et al., 2014
Tanas et al., 2011
GNAQ/GNA11 activating mutation uveal melanoma Van Raamsdonk et al., 2009
Van Raamsdonk et al., 2010Therapeutic Targeting of Hippo Signaling
The core Hippo pathway is a kinase cascade, and protein ki-
nases are usually druggable. Thus, inhibitors for MAP4K4,
MST1/2, or LATS1/2 may be developed to induce YAP/TAZ ac-
tivity and facilitate the process of wound healing, tissue repair, or
regeneration and possibly for treating degenerative diseases
(Figure 4). For example, temporal inhibition of MST1/2 or
LATS1/2 may promote myocardial regeneration or survival that
would be beneficial for heart attack patients. It is also possible
that inhibitors of MST1/2 or LATS1/2 could be used for treating
hematological cancers.
Generally, MST1/2 and LATS1/2 are tumor suppressors, and
inhibition of MST1/2 or LATS1/2 may promote tumor growth in
most instances. On the other hand, inhibiting YAP/TAZ activity
would offer a new and attractive anti-cancer strategy (Park
and Guan, 2013). The function of YAP/TAZ is primarily mediated
by TEADs, so small molecules disrupting the YAP/TAZ-TEAD
interaction will function as YAP/TAZ inhibitors. Indeed, porphyrin
family molecules, especially verteporfin, are able to disrupt the
interaction between YAP/TAZ and TEADs, and verteporfin can
block transcription of YAP/TAZ target genes and suppress liver
overgrowth induced by YAP overexpression or NF2 inactivation
in mice (Liu-Chittenden et al., 2012). However, verteporfin has
general cellular toxicity and low aqueous solubility. Based on
structural information from the YAP-TEAD and VGLL4-TEAD
complex, a polypeptide termed ‘‘super-TDU’’ has been de-
signed to block YAP-TEAD interaction and has been shown to
suppress tumor growth in mouse models (Jiao et al., 2014).
It is challenging to design direct activators for protein kinases.
However, LATS1/2 may be activated indirectly by molecules tar-geting their upstream regulators. The very first small molecule
(dobutamine) identified with an inhibitory effect on YAP is an
antagonist of a GPCR receptor (Bao et al., 2011). Since then,
many indirect inhibitors for YAP/TAZ have been identified,
including phosphodiesterase inhibitors rolipram and ibudilast
(Yu et al., 2013a). The Rho family GTPases have a strong inhib-
itory effect on LATS1/2, and membrane localization is important
for Rho cellular function. Indeed, mevalonate metabolic pathway
inhibitor statins can block membrane translocation of Rho
GTPases and indirectly inhibit YAP/TAZ activity (Mi et al.,
2015; Sorrentino et al., 2014; Wang et al., 2014). It will be inter-
esting to test whether these drugs are effective in suppressing
tumor growth in mouse models and to perform epidemiologic
studies to determine whether patients using statins or rolipram
have a lower incidence of cancer. Given the important function
of the Hippo pathway in regulating cell proliferation and tissue
homeostasis, it represents an exciting and previously unex-
plored field for cancer therapy.Outstanding Questions
Despite the rapid research progress in the Hippo pathway, some
key questions remain unanswered, and new questions are
emerging. Listed below are some of the key questions in the
Hippo field.
(1) What are the molecular mechanisms regulating MST1/2
activity? Many upstream signals have been convincingly
shown to regulate LATS1/2 phosphorylation and kinase
activity. However, neither MST1/2 phosphorylation nor
its kinase activity is strongly modulated by upstreamCell 163, November 5, 2015 ª2015 Elsevier Inc. 821
Figure 4. Therapeutic Targeting of the Hippo Pathway
(A) Potential roles of YAP/TAZ activity in tissue development and diseases.
A confined window of YAP/TAZ activity is required for normal tissue devel-
opment and homeostasis.
(B) Strategies for targeting YAP/TAZ activity. Inhibitors for MST1/2, MAP4K4,
and LATS1/2 can activate YAP/TAZ. YAP/TAZ-TEAD interaction may be dis-
rupted by small molecules directly (Verteporfin) or AMPK activators (Metfor-
min). Small molecules inhibiting Rho-family GTPases or ROCK can indirectly
activate LATS1/2, leading to YAP/TAZ inhibition.
822signals. Drosophila misshapen (a member of MAP4K in
mammals) acts upstream of Wts. An interesting question
is whether MST1/2 and MAP4Ks mediate different or
similar upstream signals to activate LATS1/2.
(2) Where are Hippo pathway components localized in
mammalian cells? This may be key to understanding
how the Hippo pathway is regulated in response to up-
stream signals. It is obvious that phosphorylated YAP/
TAZ are enriched in the cytoplasm and dephosphorylated
YAP/TAZ in the nucleus. However, it is less clear where
YAP/TAZ phosphorylation and dephosphorylation occur.
A related question is what are the mechanisms underlying
YAP/TAZ translocation between the nucleus and cyto-
plasm?
(3) How are LATS1/2 regulated by actin remodeling and/or
cellular tension? This is one of the key questions in under-
standing the biochemical mechanism of the Hippo kinase
cascade regulation. Accumulating evidence suggests
that the actin cytoskeleton and cellular tension play a
key role in LATS1/2 regulation and appear to act down-
stream of many, if not most, upstream signals. The actin
cytoskeleton and cellular tension are intertwined, thus
the question is: which one plays amore direct role in regu-
lating Hippo core components?Cell 163, November 5, 2015 ª2015 Elsevier Inc.(4) What is the mechanism of organ size sensing? Although
many signals are reported to regulate the Hippo pathway
in vitro, so far none have been demonstrated to play a key
role in organ size control in vivo. Uncovering this magic
signal will solve a key question in developmental biology.
(5) How does YAP become deregulated in cancer? It is clear
that YAP/TAZ activation is observed in a broad spectrum
of human cancers, although mutations in Hippo pathway
genes are rare. This interesting conundrum indicates that
the Hippo pathway may be regulated broadly by many
other cancer-driving pathways.
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